Summary of DuPont's Investor Day 2025 Company Overview - **Company**: DuPont - **Event**: Investor Day 2025 - **Key Themes**: Transformation, innovation, and acceleration [1][2] Financial and Strategic Highlights - **Pro Forma Basis**: Presentation based on the new DuPont after the spin-off of Delrin and divestiture of the Aramids business [2] - **New Reporting Segments**: Focus on healthcare, water technologies, and diversified industrials [2] - **Timeline**: Spin-off expected on November 1, 2025, and divestiture completion in Q1 2026 [2] Key Messages from Leadership 1. **Transformation Execution**: Focus on portfolio and operational transformation to reduce complexity and cyclicality [7] 2. **Excellence Focus**: Codifying innovation excellence and operational excellence into a comprehensive business system [8] 3. **Growth Acceleration**: Half of the businesses positioned in markets growing above GDP, with continued investment in these areas [8] 4. **Capital Allocation**: Disciplined model to deliver strong returns for shareholders [9] 5. **Cultural Enhancement**: Building a culture focused on growth and continuous improvement [9] Financial Performance and Projections - **Revenue Growth**: Divestiture of the Aramids business expected to increase revenue growth by 50 basis points and margin by 90 basis points [10] - **Long-term Targets**: Projecting 3-4% organic growth CAGR, margin expansion of 150-200 basis points by 2028, and EPS growth of 8-10% [25][26] Business Segments Healthcare and Water Technologies - **Sales Contribution**: Healthcare and water technologies each represent about 25% of sales [13] - **Market Position**: Leading position in medical devices, biopharma, and water filtration [34][42] - **Growth Drivers**: Aging population, chronic diseases, and increasing demand for clean water [38][46] - **Expected EBITDA Margin**: Approximately 30% for the Healthcare and Water segment [34] Diversified Industrials - **Sales Contribution**: Represents about 50% of DuPont's portfolio [14] - **Market Leadership**: Strong presence in construction, automotive, aerospace, and industrial sectors [55] - **Sales and Margin**: $3.6 billion business with a 22% operating margin [55] - **Growth Opportunities**: Focus on energy efficiency, sustainability, and innovation in product offerings [62][63] Innovation and R&D - **Investment Focus**: Emphasis on innovation to drive growth, with a vitality index of 30% [16] - **New Product Sales**: 40% growth and 60% renew, with plans to shift towards more growth [16] - **Customer Collaboration**: Strong partnerships with leading medical device and biopharma companies [41] Market Opportunities - **Addressable Market**: Combined addressable market of over $40 billion [14] - **Sustainability Trends**: Increasing focus on sustainability and regulatory requirements driving growth in water technologies [46][48] Conclusion - **Commitment to Excellence**: DuPont aims to enhance shareholder value through disciplined capital decisions and consistent delivery of growth and margin expansion [26][27] - **Future Outlook**: Positioned to lead in innovation and sustainability, with a strong focus on operational excellence and customer collaboration [69][70]

Core Insights - DuPont de Nemours, Inc. has a market capitalization of $31.9 billion and operates in specialty materials and chemicals, serving various markets including electronics, industrial, healthcare, water, and protection [1] - The company is categorized as a large-cap stock due to its valuation exceeding $10 billion, with strengths in intellectual property, strong margins, and exposure to high-growth markets [2] Stock Performance - DuPont's shares have declined 13.4% from a 52-week high of $90.06 reached on September 27, 2024, and have decreased 12.4% over the past three months, underperforming the Materials Select Sector SPDR Fund's 5.2% rise [3] - Year-to-date, DuPont's stock is up 2.3%, lagging behind the XLB's 10.1% return, and has dipped 2.4% over the past 52 weeks compared to XLB's 1.8% rise [4] Recent Developments - On August 29, DuPont announced a definitive agreement to sell its Aramids business, including Kevlar® and Nomex®, to Arclin for approximately $1.8 billion, expected to close in Q1 2026 pending regulatory approvals [5] - The transaction is anticipated to provide DuPont with about $1.2 billion in pre-tax cash proceeds, a $300 million note receivable, and a 17.5% equity stake in the future Arclin entity valued at roughly $325 million at closing [5] - Management indicated that this transaction enhances DuPont's strategic focus and growth profile, but the market reaction was negative, with shares dipping 1.5% in the following trading session [6]